Medical Device News Magazine

Gesund.ai Exits Stealth with $2M in Funding

Funds to Be Used to Build the Highway of Clinical-Grade AI for Safe and Effective Medical Applications

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Gesund.ai, the company ensuring that medical artificial intelligence (AI)  is safe and effective, today exits stealth and announces $2M in seed funding led by 500 Global.

The company is also releasing a community edition of its platform free to academics and unveiling its advisory board that includes; The Honorable Dr. David Shulkin, M.D., the 9th US Secretary of Veterans Affairs, former president and CEO of Beth Israel Medical Center in New York; Bryan Sivak, former CTO of US Department Health and Human Services and former Managing Director of Kaiser Permanente Ventures; Dr. Paul Chang, M.D., a radiology professor at UChicago Medical Center.

Gesund combines an off-the-shelf machine learning operations (MLOps) toolbox and graphical user interface (GUI) with an explainability layer based on a low-code platform to allow non-programmers, e.g., physician-scientists or ML scientists, to run algorithms against new data sets and explore algorithm efficacy. Critically, this platform untangles the bottleneck of limited data by connecting curated and diverse data sets to innovative companies in a HIPAA-compliant fashion so they can more quickly and efficiently bring AI algorithms to market. Gesund’s clinical partners include UChicago Medical Center and Massachusetts General Hospital in the U.S., Berlin’s Charité, the largest university hospital in Europe. The immediate focus of the platform is solving the lack of contract research organizations (CROs) in the medical AI space, which is currently dominated by imaging/radiology applications.

Traditional CROs conduct clinical trials for drug and medical device companies to validate safety and efficacy on the way to regulatory clearance from the FDA. Gesund is providing CRO-like services for medical AI algorithms given traditional CROs, as well as regulatory bodies, lack the appropriate tools and data access for evaluation purposes.

“AI systems are only as good as the data used to train them but healthcare data is extremely fragmented across different providers, insurance companies, pharmacy records, and even consumer-generated data like fitness trackers,” explains Enes Hosgor, Ph.D., CEO and founder of Gesund. “We’re ensuring that AI is truly clinical grade and equitable by providing scalable and compliant access to standardized yet diverse data through a low-code MLOps platform.”

Artificial intelligence holds great potential for improving healthcare in ways that include improving preventative medicine and new drug discovery, which is why AI in healthcare is expected to grow at 48% annualized between 2017 and 2023, But the still-nascent nature of AI in healthcare carries risks of injuries and errors with the lack of data availability, cited in a recent report as a critical limiting factor to developing effective healthcare AI.

Overcoming those limitations is complicated by the fact that hospital IT systems are high-compliance environments that don’t fit with traditional MLOps stacks, which rely on third-party managed services used by traditional MLOps that complicate privacy compliance. Gesund’s proprietary and lightweight MLOps stack works both on-premise and via the cloud without strictly relying on containerization, like Docker, or orchestration, like Kubernetes, which is often a roadblock in high-compliance environments.

“AI can do so much to improve health outcomes but we first have to solve the lack of access to data that’s keeping its potential mired in gridlock,” says Enis Hulli, General Partner at 500 Global. “Gesund’s superhighway of clinical-grade AI is exciting because it clears the way to safer, more effective tools to help improve medical outcomes for patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”